Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Breast Neoplasms 402Triple Negative Breast Neoplasms 64Neoplasm Metastasis 50Neoplasms 19Breast Neoplasms, Male 14Colorectal Neoplasms 13Brain Neoplasms 13Stomach Neoplasms 11Pancreatic Neoplasms 11Colonic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Inflammatory Breast Neoplasms 6HER2-positive Breast Cancer 6Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Advanced Breast Cancer 5Rectal Neoplasms 4HER2 Positive Metastatic Breast Cancer 4Breast Cancer Metastatic 4Sarcoma 3Prostatic Neoplasms 3Meningeal Neoplasms 3Lymphoma, Non-Hodgkin 3Gallbladder Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Small Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Unknown Primary 2

Interventions

tucatinib 1temsirolimus 1pembrolizumab 1niraparib 1lenvatinib 1atezolizumab 1Valproic Acid 1Trastuzumab 1Tissue Banks 1Sirolimus 1Immunoglobulin G 1Fulvestrant 1Doxycycline 1Disulfides 1Cetuximab 1Capecitabine 1Blood Specimen Collection 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Capecitabine × Breast × Clear all
NCT02915172 2017-06-26

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Withdrawn
BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡